Literature DB >> 21811750

Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.

Vladimíra Vojtová1, Milan Kolár, Kristýna Hricová, Radek Uvízl, Jan Neiser, Ladislav Blahut, Karel Urbánek.   

Abstract

Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21811750

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  8 in total

1.  Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Authors:  Waroonrat Sukarnjanaset; Sutep Jaruratanasirikul; Thitima Wattanavijitkul
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-08       Impact factor: 2.745

2.  The antimicrobial efficacy of silver on antibiotic-resistant bacteria isolated from burn wounds.

Authors:  Steven L Percival; John Thomas; Sara Linton; Tyler Okel; Linda Corum; Will Slone
Journal:  Int Wound J       Date:  2011-12-19       Impact factor: 3.315

3.  Role of MexA-MexB-OprM efflux pump system in chronic Pseudomonas aeruginosa pulmonary infection in mice.

Authors:  Fengyun Gong; Weili Zhan; Lili Wang; Ying Song; Mingyou Xing; Jianxin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

Review 4.  β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.

Authors:  Hosam M Zowawi; Hanan H Balkhy; Timothy R Walsh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Evaluation of Synergistic Interactions Between Cell-Free Supernatant of Lactobacillus Strains and Amikacin and Genetamicin Against Pseudomonas aeruginosa.

Authors:  Sargol Aminnezhad; Rouha Kasra Kermanshahi; Reza Ranjbar
Journal:  Jundishapur J Microbiol       Date:  2015-04-18       Impact factor: 0.747

6.  Purification and synergistic antibacterial activity of arginine derived cyclic dipeptides, from Achromobacter sp. associated with a rhabditid entomopathogenic nematode against major clinically relevant biofilm forming wound bacteria.

Authors:  Indira Deepa; Sasidharan N Kumar; Ravikumar S Sreerag; Vishnu S Nath; Chellapan Mohandas
Journal:  Front Microbiol       Date:  2015-08-25       Impact factor: 5.640

7.  The Potential Role of Social Media Platforms in Community Awareness of Antibiotic Use in the Gulf Cooperation Council States: Luxury or Necessity?

Authors:  Hosam Mamoon Zowawi; Malak Abedalthagafi; Florie A Mar; Turki Almalki; Abdullah H Kutbi; Tiffany Harris-Brown; Stephan Harbarth; Hanan H Balkhy; David L Paterson; Rihab Abdalazez Hasanain
Journal:  J Med Internet Res       Date:  2015-10-15       Impact factor: 5.428

8.  Pseudomonas aeruginosa in the ICU: prevalence, resistance profile, and antimicrobial consumption.

Authors:  Ághata Cardoso da Silva Ribeiro; Márcia Terezinha Lonardoni Crozatti; Adilson Aderito da Silva; Rodrigo Spineli Macedo; Antonia Maria de Oliveira Machado; Antonio Távora de Albuquerque Silva
Journal:  Rev Soc Bras Med Trop       Date:  2019-12-20       Impact factor: 1.581

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.